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A B S T R A C T
Objectives: This study aimed to investigate patients’ willingness to initiate a preventive treatment and
compared two established effect measures to the newly developed Delay of Events (DoE) measure that
expresses treatment effect as a gain in event-free time.
Methods: In this cross-sectional, randomized survey experiment in the general Swedish population,1079
respondents (response rate 60.9%) were asked to consider a preventive cardiovascular treatment.
Respondents were randomly allocated to one of three effect descriptions: DoE, relative risk reduction
(RRR), or absolute risk reduction (ARR). Univariate and multivariate analyses were performed
investigating willingness to initiate treatment, views on treatment beneﬁt, motivation and importance
to adhere and willingness to pay for treatment.
Results: Eighty-one percent were willing to take the medication when the effect was described as DoE,
83.0% when it was described as RRR and 62.8% when it was described as ARR. DoE and RRR was further
associated with positive views on treatment beneﬁt, motivation, importance to adhere and WTP.
Conclusions: Presenting treatment effect as DoE or RRR was associated with a high willingness to initiate
treatment.
Practice implications: An approach based on the novel time-based measure DoE may be of value in clinical
communication and shared decision making.
ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patients’ understanding of a proposed medication’s effective-
ness is central to evidence-based medicine and medical decision-
making. Informed shared decision-making is possible when a
patient has an adequate understanding of their medical situation/
increased risk including a sound understanding of the expected
beneﬁts from treatment. It is well documented that the way
treatment information is presented inﬂuences patients’ under-
standing and decisions to initiate and adhere to a proposed
treatment [1–3]. This is of special concern in the prevention of
chronic diseases, where the treatment goal is to prevent or delay
major disease events or premature death. Long-term adherence to
such chronic treatments is known to be poor [4]. Insufﬁcient
adherence to cardiovascular preventive treatments is associated* Corresponding author. Current Address: Department of Public Health and
Caring Sciences, Uppsala University, Box 564, SE-751 22 Uppsala, Sweden.
E-mail address: erik.berglund@pubcare.uu.se (E. Berglund).
http://dx.doi.org/10.1016/j.pec.2016.07.028
0738-3991/ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access a
nd/4.0/).with increased morbidity [5–7], and thus nonadherence is
considered to be a cardiovascular risk factor [8].
The way a treatment’s effect is presented has been shown to
inﬂuence decisions by patients as well as physicians [1,9]. It is
therefore of clinical interest to determine the optimal way of
describing treatment effect that increases patients’ willingness to
initiate and adhere to treatment.
Commonly used measures describing preventive treatment
effect include relative risk reduction (RRR), absolute risk reduction
(ARR) and number-needed-to-treat (NNT) [10]. These measures
compare the proportion of events in relative and absolute terms in
two compared trial arms. While these measures are methodologi-
cally justiﬁed, they may be difﬁcult to use in shared decision-
making as people typically have difﬁculties understanding
proportional measures [11–13]. ARR and its inverse, NNT, have
the advantage of presenting the effect as absolute ﬁgures.
However, research has shown that presenting beneﬁt as ARR or
NNT is suboptimal when communicating treatment beneﬁts
[14,15]. RRR typically comes out as more favorable than ARR and
NNT when comparing patients’ willingness to initiate treatmentrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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the baseline risk. Several authors have proposed that these
established effect measures may be complemented by other
estimates providing the effect on the time dimension of interest
[16–18]. Time-based effect measures of treatment effect are of
interest in shared clinical decision-making as such measures seem
to be preferable and easier to comprehend for laypeople as well as
health care professionals [19,15,20]. Previous studies investigating
the role of different effect measures in medical decision-making
have used time-based measures based on extrapolation of data
[21], which raises questions about the correctness and compara-
bility. With the goal of combining the clinical beneﬁts of time-
based measures with the rigor of statistical calculated measures, a
relatively new way of demonstrating treatment on a timescale has
been proposed [22]. DoE may be estimated modelling survival
percentiles with Laplace regression, a statistical method appropri-
ate for censored quantiles and survival distribution [23]. The DoE
may be understood as the horizontal difference between a
treatment arm and control arm in a Kaplan-Meier curve. Delay
of Events is an absolute measure that is conditional on the event,
which means that if a patient has the event without treatment
during the follow-up period, the DoE depicts the time that event
may be delayed by due to treatment. Thus, DoE captures the
magnitude of the effect expressed as a gain in disease-free time for
treated compared to untreated patients.
The objective of this study is to compare the established
proportional effect measures, RRR and ARR, with the novel time-
based measure DoE, to determine how the different formats affectFig. 1. The ﬂow diagram shows group allocation and number of respondents in each grou
described as RRR and group C received information described as ARR.a person’s willingness to initiate a preventive medication
treatment. A secondary objective is to investigate how the different
ways of demonstrating treatment effect affect individuals’ views
on treatment beneﬁt, motivation to initiate and adhere to
treatment, and willingness to pay for treatment [24,25].
2. Methods
2.1. Design and sample
This is a cross-sectional postal questionnaire study in a
population-based sample (age 45–75). We randomly selected
1800 people from the Swedish national population registry. The
sample was then further randomized into three equally sized
groups (A, B and C), which received different treatment effect
information about a hypothetical cardiovascular treatment, further
described below. The questionnaire was returned by 1079
individuals who gave informed consent to participate. Fourteen
questionnaires were returned unopened to the sender by the mail
service, as the recipient could not be reached/were no longer living
at the address. Thirteen recipients declined to participate, and 694
persons did not answer at all, making the response rate of the
distributed questionnaires 60.4% (1079/1786). The response rate in
the three groups varied from 56.8% to 65.2%. Data were collected
from November 2013 to February 2014. Fig. 1 presents a ﬂow chart
of the study. Those how declined to participate did that either by
sending us a letter or email or thru telephone.p. Group A received treatment effect described as DoE, group B received information
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The postal questionnaire contained a total of 55 questions.
Demographic data were collected through questions that assessed
the respondents’ gender, age and educational level (categorized as
compulsory school, secondary school or university). History of
heart attack and/or angina was assessed with questions used in
previous studies [26,27]. Data were also collected regarding
whether the respondents were on current medical treatments,
and if so, the number of prescription drugs. The written
information about the effects and the outcome questions were
tested in a pilot study and modiﬁed afterwards before they were
included in this questionnaire.
2.2.1. Written information and survey experiment
This study was performed as a survey experiment [28,29]. All
respondents were asked to imagine that they were at increased
risk of cardiovascular disease, and that their physician had
suggested a preventive cardiovascular drug treatment. The text
was as follows: “Imagine that in the next ﬁve years you will have an
increased risk of having a heart attack. Your physician offers you a
drug, with infrequent and mild side effects, which is to be taken
orally once daily. The usefulness of the drug has been evaluated in
scientiﬁc studies, and the effect can be described as follows:” The
following text described the effect differently based on group
allocation, where the ﬁrst group (A) received treatment effect
described as Delay of Events, the second group (B) received
information described as RRR and the third group (C) received
information described as ARR (see Table 1). The different ways of
displaying the same treatment beneﬁt were all derived and
calculated from the Scandinavian Simvastatin Survival Study (4S), a
randomized controlled trial presenting the ﬁrst evidence that
statin treatment improves survival in patients with coronary heart
disease [30]. In this survey the DoE ﬁgure was assessed at the end
of the 4 S study, at the same time as the point estimates for the
other measures. The scenario and outcome questions was pre-
tested in a primary care pilot survey (n = 180) and then adjusted
and ﬁnalized into its present form. The phrasings and methods are
similar to other studies investing different ways of explaining
medication beneﬁt [31]. NNT was not included since previous
research has found that the NNT measures are ineffective for
communicating treatment beneﬁts [14,15].
2.2.2. Outcome variables
Information about willingness to initiate treatment was
assessed using the question: “If you were in the same situation
as the person in this case would you initiate treatment?” Answers
were dichotomous: “yes” or “no.” Other questions that were used
to evaluate the views on the treatment were: “To what extent does
the description help you make a medical decision?”; “How much
beneﬁt do you think that the drug would have?”; “Would you feel
safe to take the drug?”; “Would you, based on the description, beTable 1
Three different ways of communicating treatment information.
Shared setting Imagine that in the next ﬁve years you will have an in
mild side effects, to be taken in pill form once daily. The
described as follows:
Group Effect measure Magnitude Text in survey
A. Delay of events (DoE) 18 months If you have a heart attack in the next ﬁv
B. Relative risk
reduction (RRR)
27% If you take the treatment for ﬁve years, 
C. Absolute risk
reduction (ARR)
2% Without treatment, your risk of a heart a
attack in the next ﬁve years will be 6%.motivated to take the medication on a daily basis?”; and “How
important do you consider it to adhere to the treatment?” The
answers to these questions were assessed on seven-point Likert
scales ranging from 1 (not at all) to 7 (very much). Willingness to
pay is an assessment of the (maximum) amount of money that
must be paid by an individual to equalize a utility change [25]. To
evaluate willingness to pay (WTP), the contingent valuation
method (CVM) was used. The CVM is a questionnaire-based
method ﬁrst proposed as a method for eliciting market valuation of
nonmarket goods and public goods [24,25]. The method is widely
used to elicit the monetary value a person is willing to pay for
health-care services [32], and likewise as a complementary
measure of the expected utility. In this study WTP was assessed
by one open-ended question: “What is the maximum amount you
would pay per month over a ﬁve-year period to receive the
treatment?” WTP was assessed in Swedish currency (SEK), and was
converted in this study to euros (s) at an exchange rate of 0.10.
2.3. Statistical analysis
Differences in proportions between groups were tested using
Chi-square analyses, and differences in ordinal data were assessed
using the Kruskal-Wallis H test. Pairwise comparisons were
performed with the Mann-Whitney U test using Bonferroni
correction to maintain the risk of type 1 error at 0.05 [33]. In
Bonferroni correction for pairwise comparisons among three
groups, the signiﬁcance level is set to a p-value  0.017 (0.05/
3  0.017). Binary logistic regression models were used to analyze
associations between different effect prescriptions, gender, age,
education level, history of heart disease, number of prescribed
medications and willingness to initiate treatment. Sample size was
determined prior to the study to have an 80% power to determine a
10% difference in proportion to the main outcome with a
signiﬁcance level of 0.05%. The Statistical Package for the Social
Sciences (SPSS) version 20 (IBM SPSS Statistics for Windows,
Armonk, NY: IBM Corp Chicago, IL, USA) was used for descriptive
statistics and statistical tests.
2.4. Ethical consideration
The study was approved by the regional Ethical Committee of
Clinical Investigation in Uppsala. Participation was voluntary and
performed under informed consent.
3. Results
The study population was on average 61.9 years old and
consisted of slightly more women than men. Secondary school was
the most common completed education level. The distribution of
demographic variables, overall and according to group allocation,
is shown in Table 2.creased risk of having a heart attack. Your physician offers you a drug with rare and
 usefulness of the drug has been evaluated in scientiﬁc studies, and the effect can be
e years it will be delayed by up to 1.5 years if you take the treatment.
you will reduce the risk of a heart attack by 27%.
ttack in the next ﬁve years is 8%, and if you take the treatment, the risk of a heart
Table 2
Distribution of characteristics among participants.
Category Subcategory DoE RRR ARR Overall
Gender Women, % (n) 55.7 (186) 49.2 (174) 55.1 (211) 53.3 (571)
Men, % (n) 44.3 (148) 50.8 (180) 44.9 (172) 46.7 (500)
Age Mean (s.d.) 61.8 (8.6) 62.2 (8.7) 61.6 (8.7) 61.9 (8.5)
Education level Compulsory school, % (n) 27.5 (92) 28.7 (100) 27.1 (103) 27.8 (295)
Secondary school, % (n) 35.8 (120) 38.8 (135) 37.6 (143) 37.4 (398)
University, % (n) 36.7 (123) 32.5 (113) 35.3 (134) 34.8 (370)
History of cardiovascular diseases No heart attack, % (n) 97.3 (321) 95.4 (330) 95.8 (363) 96.1 (1014)
Heart attack, % (n) 2.7 (9) 4.6 (16) 4.3 (16) 3.9 (41)
No angina, % (n) 96.4 (318) 94.3 (328) 97.4 (369) 96.0 (1015)
Angina, % (n) 3.6 (12) 5.8 (20) 2.6 (10) 4.0 (42)
Quantity of prescription medications No use, % (n) 39.0 (124) 38.0 (125) 42.8 (154) 40.0 (403)
1, % (n) 20.4 (65) 16.7 (55) 16.1 (58) 17.7 (178)
4–2, % (n) 30.2 (96) 31.0 (102) 31.9 (115) 31.1 (313)
>5, % (n) 10.4 (33) 14.3 (47) 9.2 (33) 11.2 (113)
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In the study population, 6.5% reported a history of established
cardiovascular disease. The reported medical history of heart
attack was 3.9% and for angina 4.0% (see Table 2). Signiﬁcantly
more men (10.0%) than women (3.4%) reported a history of
cardiovascular disease (p < 0.001).
About 60% of the group used one or more prescribed
medications. There were no signiﬁcant sex differences regarding
use of prescription medication.
3.2. Willingness to initiate treatment
A total of 80.5% were willing to take the medication when the
effect was described as DoE, 83.0% when it was described as RRR
and 62.8% when it was described as ARR. Pairwise comparisons
revealed that there were signiﬁcant differences between DoE and
ARR (p < 0.001), and between RRR and ARR (p < 0.001), but not
between DoE and RRR (P = 0.396) (see Table 3). The willingness to
initiate treatment was further investigated in multiple logistic
regressions using the different effect descriptions as independent
variables (see Table 4). There was a signiﬁcantly higher willingness
to initiate treatment in the fully adjusted models when the effect
was described as DoE (OR 2.64, 95% CI 1.81–3.85) and RRR (OR 3.12,
95% CI 2.11–4.61) as compared to ARR.
3.3. Views on treatment and WTP
There were signiﬁcant differences regarding respondents’
views on the beneﬁt from treatment, motivation to take treatment,
the importance of adhering to treatment and WTP.Table 3
Treatment decision and views of treatment according to different treatment descriptio
Outcome DoE RRR 
Willingness to initiate treatment, % (n) 80.5 (268) 83.0 (288) 
Use of information, md (q1, q3) 5 (4,6) 5 (4,6) 
Beneﬁt from medication, md (q1, q3) 5 (4,6) 5 (3,6) 
Feel safe with medication, md (q1, q3) 4 (3,6) 4 (3,5) 
Be motivated to take medication, md (q1, q3) 5 (3,6) 5 (4,6) 
Importance to adhere, md, (q1, q3) 6 (5,7) 6 (5,7) 
Willingness to payc (Euro), md (q1, q3), mean 20 (10,30), 25.7 15 (10,30), 
a Pearson Chi-Square.
b Kruskal-Wallis H test.
c Willingness to pay was measured in Swedish krona (SEK) 1 SEK/0.10 Euro (s).In pairwise comparisons, DoE scored higher than ARR in
assessments of beneﬁt from treatment (p < 0.001), motivation to
take treatment (p < 0.001) and importance to adhere (p = 0.005)
(see Table 3). RRR scored higher than ARR in assessments of beneﬁt
from treatment (p < 0.001) and motivation to take treatment
(p < 0.001). There were no signiﬁcant differences between DoE and
RRR in pairwise comparisons.
The median WTP for the three different treatment descriptions
was s20 for DoE, s15 for RRR and s10 for ARR. In pairwise
comparisons, WTP for DoE was signiﬁcantly higher than that of
ARR (p = 0.001), WTP for RRR was also signiﬁcantly higher than
that of ARR (p = 0.008). There were no signiﬁcant differences
between DoE and RRR in terms of WTP (p = 0.353).
4. Discussion
The objective of this study was to compare the proportional
effect measures, RRR and ARR, with the time-based measure, DoE,
to assess their association with people’s willingness to initiate a
preventive medication treatment. A further aim was to assess
whether the different treatment effect descriptions affected
favorable views and WTP in relation to the proposed medication.
A higher proportion of individuals were willing to initiate the
treatment when the effect was presented as DoE or RRR than as
ARR. Previous studies have shown that patients prefer medication
when the beneﬁt is presented in relative rather than in absolute
terms [34]. The results in this study imply that DoE might serve as
an adequate alternative or complement to other established
measures. The results also imply that DoE and RRR are superior to
ARR when it comes to giving patients positive views of the
treatment effects as well as motivating them to take it.ns.
ARR Overall Test statistics p-value
62.8 (238) 75.0 (794) 47.24a <0.001
5 (4,6) 5 (4,6) 0.61b 0.736
4 (2,5) 4 (3,6) 34.57b <0.001
4 (2,6) 4 (3,6) 2.29b 0.318
4 (2,6) 5 (3,6) 27.56b <0.001
6 (4,7) 6 (5,7) 8.53b 0.014
22.9 10 (5,25), 18.9 10 (8.3,30), 22.5 13.17b 0.001
Table 4
Results of logistic regression models of factors predicting patients’ willingness to initiate treatment.
Crude OR 95% CI Model 1 OR 95% CI Model 2 OR 95% CI
Treatment information Effect description:
ARR 1 1 1
DoE 2.44** (1.74–3.44) 2.67** (1.86–3.83) 2.64** (1.81–3.85)
RRR 2.89** (2.04–4.10) 3.18** (2.20–4.60) 3.12** (2.11–4.61)
Demographic Gender:
Female 1 1 1
Male 0.95 (0.72–1.25) 0.88 (0.65–1.19) 0.95 (0.69–1.31)
Age 1.07** (1.05–1.09) 1.07** (1.05–1.09) 1.05** (1.03–1.07)
Education level:
University 1 1 1
Secondary school or equal 3.27** (2.17–4.91) 2.54** (1.65–3.92) 2.25** (1.44–3.52)
Compulsory school 1.26 (0.92–1.72) 1.40 (0.99–1.95) 1.21 (0.85–1.72)
Health-related factors History of heart attack:
No heart attack 1 1
One or more heart attack 3.13* (1.10–8.86) 1.11 (0.35–3.54)
History of angina:
No angina 1 1
One or more angina attack 7.03** (1.69–29.27) 5.53 (0.71–43.33)
Prescribed medications:
No use 1 1
One 15* (1.4–2.26) 1.44 (0.94–2.21)
Two to four 3.02** (2.09–4.37) 2.32** (1.56–3.44)
Five or more 5.71** (2.89–11.28) 3.12** (1.49–6.54)
Nagelkerke r2 – 0.18 0.21
Odds ratio (OR), signiﬁcance level and conﬁdence interval (CI) for the binary logistic regressions.
Model 1 = Treatment information + gender + age + education level + occupation.
Model 2 = Model 1 + history of heart attack + history of angina + prescribed medications.
* p  0.05.
** p  0.01.
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for DoE and RRR than for ARR, implying that a gain in disease-free
time is valuable to individuals.
There is a critical difference between the compared measures.
Proportional measures, such as RRR and ARR depict treatment
beneﬁts as increased chances of avoiding disease events. While this
is true within a limited study time period, it is less likely to be true
from an individual’s lifetime perspective. Chronic diseases, such as
cardiovascular disease, develop over the life course and preventive
interventions are from that perspective more likely to delay
disease events rather than fully avoid them. RRR is a well-
established effect measure. It is suitable since it gives an estimate
of the risk reduction from the individual point of view. RRR may,
however, be problematic in shared decision-making as, if rightfully
used, it pre-assumes that the decision-maker has a sound
understanding of the baseline risk, which is rarely likely to be
the case. Furthermore, it is difﬁcult to intuitively say when an RRR
is low or high, and lay people seem to have difﬁculties in
discriminating between levels of effectiveness in RRR [12]. For
these reasons, health professionals may choose to use absolute
measures or its mathematical reciprocal, NNT, when describing a
treatment’s effect. These measures are, however, also problematic
as they are time- and population-speciﬁc and display the group
perspective, which is not optimal in individual shared decision-
making.
Relative and absolute risk reductions are point estimates,
which means that they are summary statistics of group
differences at a speciﬁc point in time: usually at the end of
the follow-up. DoE is not a point estimate, but a curve of how
the effect is delayed (or hastened) during the follow-up period
[22]. The Delay of Event measure demonstrates treatment effect
as a gain in disease-free time, which captures the magnitude of
treatment effect from the individual perspective. Since the DoEis conditional having an event, if untreated, a patient has to
assume to have the event in the time period corresponding to
the clinical study follow-up to understand the beneﬁt as DoE.
This means that patients, in contrast to the RRR, intrinsically
face the question about their own absolute base line risk. Time-
based effects have been shown to be more easily understood
than other ﬁgures [15]. Statements about time periods can be
understood differently by people and patients in treatment
situations. Time can be seen as a scarce resource [35], and when
time is related to health it may be an even more scarce
resource. When time is a part of consumer models it is often
viewed as less transferable than other “types” of wealth [35];
uncertainty in relation to time may also be more aversive [35].
This makes planning in terms of time especially important for
individuals; conversely uncertainty can disrupt planning, and
makes planning more difﬁcult. The DoE curve may also apply to
the patient lifetime perspective as it likely increases with
treatment time, in contrast to the RRR. If the curve shows an
increased effect throughout the treatment period, this may
encourage persons to continue treatment beyond the time
frames from controlled clinical trials. Consequently, an effect
measure that describes a time period, such as DoE, may be of
great importance in helping people with their planning, and
medical decision-making. DoE as a communication strategy
may be of certain value in increasing treatment uptake in
patients with poor health literacy when simple and direct
diction is desirable [36].
The Delay of Event measure calls for a shift in thinking of events
of chronic disease as delayable rather than fully avoidable. This is
arguably a justiﬁed view given the underlying pathology and that
the risk of events increases with age for most chronic disease. This
shift in thinking may affect patient's views on preventive treat-
ments' ability as well as their view of the disease itself. It is possible
2010 E. Berglund et al. / Patient Education and Counseling 99 (2016) 2005–2011that a view of disease as merely delayable with treatment affects
patient's health beliefs, health behaviors and subjective health in
both positive and negative ways. It is suggested that the effects of
viewing disease as delayable rather than avoidable is a topic for
future research.
One ﬁnding in this study was that having a history of heart
attack or angina was associated with higher patient willingness to
initiate treatment in crude analyses but not in the adjusted models.
These results may have occurred due to a small number of
respondents with a history of heart attack or angina.
4.1. Strengths and limitations
The strengths of this study include the community setting, the
randomized survey experimental approach and the manner in
which the treatment effects were presented to the respondents.
This study also has some limitations worth noting. The response
rate is reasonable in relation to what is anticipated from
questionnaire-based studies, but there was no information about
nonresponders. The hypothetical setting used in the question-
naires is, further, different from clinical situations where
information may be individualized and clariﬁed. Although many
respondents reported using medication, the study population was
a sample from the general population, which is not the same as a
targeted patient population. The data used to calculate the effect
came from a study of secondary preventive treatment, and
therefore a study population at higher risk of CVD than the
majority of the respondents in this study. Preventive treatment
effects expressed as the novel approach Delay of Events or relative
risk reduction were separately associated with a high willingness
to initiate treatment.
4.2. Conclusion
The results in this study imply that DoE and RRR are comparable
in a population setting, and that they are preferable to ARR, in
motivating individuals to initiate a treatment. Preventive treat-
ment effects expressed as the novel approach Delay of Events or
relative risk reduction were separately associated with a high
willingness to initiate treatment. Presenting preventive treatment
effect as Delay of Events or relative risk reduction was further
associated with positive views on treatment beneﬁt, motivation,
importance to adhere and willingness to pay for treatment. There
is a need to further investigate if the novel DoE may have a role in
clinical decision-making for speciﬁc patient groups and treat-
ments, especially if it may improve long-term adherence.
4.3. Practice implications
Expressing treatment effect using the novel Delay of Events
measure holds value for clinical communication and medical
decision making, and this study implies that presenting treatment
effect as Delay of Events might increase the likelihood that a
patient will accept and adhere to a proposed preventive treatment.
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